As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...

ADAR1 Capital Management LLC dramatically boosted its holdings in Regeneron Pharmaceuticals by 56.3% during Q4, grabbing 1,361 shares worth nearly $969,000. Several other institutional investors also ...

The stock's rise snapped a four-day losing streak.

Regeneron Pharmaceuticals's REGN short percent of float has risen 26.83% since its last report. The company recently reported that it has 3.25 million shares sold short, which is 3.12% of all regular ...

In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $1,081 from $1,150 and keeps an Overweight rating ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

Fmr LLC gave Regeneron the cold shoulder, trimming its stake by 20.9% and dropping 2.16 million shares in Q4. This move ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

Matteo Paz was one of the finalists who submitted an original research science project for this year's Regeneron Science ...

Auburn University and the I-Stem Connectory at AU hosted the 2025 Alabama Science and Engineering Fair on Saturday, April 5.

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on ...